- Home
- PAYO vs ZLAB Comparison
PAYO vs ZLAB Comparison
Compare PAYO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- ZLAB
- Stock Information
- Founded
- PAYO 2005
- ZLAB 2013
- Country
- PAYO United States
- ZLAB China
- Employees
- PAYO N/A
- ZLAB N/A
- Industry
- PAYO EDP Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- ZLAB Health Care
- Exchange
- PAYO Nasdaq
- ZLAB Nasdaq
- Market Cap
- PAYO 3.2B
- ZLAB 1.8B
- IPO Year
- PAYO N/A
- ZLAB 2017
- Fundamental
- Price
- PAYO $8.66
- ZLAB $31.24
- Analyst Decision
- PAYO Strong Buy
- ZLAB Strong Buy
- Analyst Count
- PAYO 7
- ZLAB 4
- Target Price
- PAYO $8.93
- ZLAB $52.50
- AVG Volume (30 Days)
- PAYO 2.0M
- ZLAB 976.3K
- Earning Date
- PAYO 11-05-2024
- ZLAB 11-12-2024
- Dividend Yield
- PAYO N/A
- ZLAB N/A
- EPS Growth
- PAYO 447.53
- ZLAB N/A
- EPS
- PAYO 0.26
- ZLAB N/A
- Revenue
- PAYO $900,058,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- PAYO $14.06
- ZLAB $48.34
- Revenue Next Year
- PAYO $7.49
- ZLAB $47.12
- P/E Ratio
- PAYO $32.93
- ZLAB N/A
- Revenue Growth
- PAYO 21.43
- ZLAB 28.16
- 52 Week Low
- PAYO $4.22
- ZLAB $13.48
- 52 Week High
- PAYO $8.60
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- PAYO 81.47
- ZLAB 70.41
- Support Level
- PAYO $8.27
- ZLAB $31.52
- Resistance Level
- PAYO $8.56
- ZLAB $36.60
- Average True Range (ATR)
- PAYO 0.16
- ZLAB 1.36
- MACD
- PAYO 0.02
- ZLAB 0.34
- Stochastic Oscillator
- PAYO 100.00
- ZLAB 58.60
About PAYO Payoneer Global Inc.
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.